Table 2. Sensitivity analyses of methotrexate and type 2 diabetes in RA patients.

Parameters and type 2 diabetes [RR QE model (95% CI)]
Mean age of subjects (years)
≤60 (n = 9): 0.61 (95% CI 0.23, 1.61)
>60 (n = 7): 0.05 (95% CI 0.01, 0.26)
Mean duration of RA (years)
≤2 (n = 2): 0.09 (95% CI 0.03, 0.27)
>2 (n = 8): 0.57 (95% CI 0.06, 4.96)
Time of follow-up (years)
≤5 (n = 7): 0.57 (95% CI 0.05, 6.69)
>5 (n = 6): 0.51 (95% CI 0.03, 9.42)
Status of T2D
Incident T2D (n = 5): 0.77 (95% CI 0.43, 1.37)
Prevalent T2D (n = 11): 0.37 (95% CI 0.01, 9.95)
Disease activity
Measured disease actvity (n = 7): 0.06 (95% CI 0.02, 0.18)
Unmeasured disease activity (n = 9): 0.61 (95% CI 0.24, 1.58)
Year of publication
≤2010 (n = 4): 0.45 (95% CI 0.12, 1.64)
>2010 (n = 12): 0.47 (95% CI 0.14, 1.59)
Country of publication
North America (USA) (n = 6): 0.67 (95% CI 0.09, 5.00)
South America (n = 2): 0.08 (95% CI 0.00, 2.81)
Asia Pacific (n = 2): 0.65 (95% CI 0.37, 1.13)
Europe (n = 6): 0.07 (95% CI 0.02, 0.18)

n = number of studies involved in the analysis, USA = United States of America